DK0812209T3 - Cochleatleveringsvehikel til biologisk relevante molekyler - Google Patents

Cochleatleveringsvehikel til biologisk relevante molekyler

Info

Publication number
DK0812209T3
DK0812209T3 DK96906334T DK96906334T DK0812209T3 DK 0812209 T3 DK0812209 T3 DK 0812209T3 DK 96906334 T DK96906334 T DK 96906334T DK 96906334 T DK96906334 T DK 96906334T DK 0812209 T3 DK0812209 T3 DK 0812209T3
Authority
DK
Denmark
Prior art keywords
biologically relevant
cochlate
delivery vehicle
relevant molecules
component
Prior art date
Application number
DK96906334T
Other languages
English (en)
Inventor
Raphael James Mannino
Susan Gould-Fogerite
Original Assignee
Univ New Jersey Med
Albany Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Jersey Med, Albany Medical College filed Critical Univ New Jersey Med
Application granted granted Critical
Publication of DK0812209T3 publication Critical patent/DK0812209T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18834—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK96906334T 1995-02-22 1996-02-22 Cochleatleveringsvehikel til biologisk relevante molekyler DK0812209T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/394,170 US5840707A (en) 1993-10-04 1995-02-22 Stabilizing and delivery means of biological molecules
PCT/US1996/001704 WO1996025942A1 (en) 1995-02-22 1996-02-22 Cochleate phospholipids in drug delivery

Publications (1)

Publication Number Publication Date
DK0812209T3 true DK0812209T3 (da) 2004-09-13

Family

ID=23557861

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96906334T DK0812209T3 (da) 1995-02-22 1996-02-22 Cochleatleveringsvehikel til biologisk relevante molekyler

Country Status (11)

Country Link
US (1) US5840707A (da)
EP (1) EP0812209B1 (da)
JP (2) JP4535211B2 (da)
AT (1) ATE265859T1 (da)
AU (1) AU4974896A (da)
CA (1) CA2212382C (da)
DE (1) DE69632395T2 (da)
DK (1) DK0812209T3 (da)
ES (1) ES2220973T3 (da)
PT (1) PT812209E (da)
WO (1) WO1996025942A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1273897A (en) * 1995-11-22 1997-06-11 University Of Washington Research Foundation Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US6180114B1 (en) 1996-11-21 2001-01-30 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6340591B1 (en) 1998-12-14 2002-01-22 University Of Maryland Integrative protein-DNA cochleate formulations and methods for transforming cells
US6153217A (en) * 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
AU2007200813B2 (en) * 1999-01-22 2010-06-03 Biodelivery Sicencies, Inc. Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
US6274555B1 (en) 2000-05-15 2001-08-14 Lisa A. Berdami Composition and method for topical animal medication
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
IL160761A0 (en) 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
US20030219473A1 (en) * 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
CA2504329C (en) 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20050008686A1 (en) * 2003-01-15 2005-01-13 Mannino Raphael J. Cochleate preparations of fragile nutrients
TWI433693B (zh) * 2003-02-14 2014-04-11 Childrens Hosp & Res Ct Oak 親脂藥物傳送媒介物及其使用方法
WO2004091578A2 (en) 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Novel encochleation methods, cochleates and methods of use
WO2004091572A2 (en) 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Cochleate compositions directed against expression of proteins
AU2004283078A1 (en) * 2003-10-01 2005-05-06 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
CA2562499A1 (en) * 2004-04-09 2005-11-24 Biodelivery Sciences International, Inc. Nucleotide-cochleate compositions and methods of use
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
US20100178325A1 (en) * 2006-08-23 2010-07-15 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
EP2109459B1 (en) 2006-12-15 2013-03-06 National Research Council of Canada Archaeal polar lipid aggregates for administration to animals
CA2678587A1 (en) * 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
WO2009015183A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
US8951563B2 (en) 2009-08-06 2015-02-10 Technion Research & Development Foundation Limited Antibiotic drug delivery and potentiation
EP2704688B1 (en) 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Cochleate compositions and methods of making and using same
CN104411316B (zh) 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
KR101989789B1 (ko) * 2017-11-30 2019-06-18 (주) 에이치엔에이파마켐 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
KR102763352B1 (ko) * 2022-01-27 2025-02-07 주식회사 한국인삼공사 인삼 유래 조사포닌의 피부 투과성이 개선된 피부손상 방지 및 주름 개선용 화장료 조성물
WO2024039733A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods
WO2024039729A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2249552A1 (de) * 1971-10-12 1973-05-30 Inchema S A Verfahren zur inkapsulation von insbesondere wasserloeslichen verbindungen
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions

Also Published As

Publication number Publication date
PT812209E (pt) 2004-09-30
AU4974896A (en) 1996-09-11
ATE265859T1 (de) 2004-05-15
US5840707A (en) 1998-11-24
ES2220973T3 (es) 2004-12-16
EP0812209A1 (en) 1997-12-17
JP4535211B2 (ja) 2010-09-01
JP2007197465A (ja) 2007-08-09
EP0812209A4 (en) 1999-11-03
CA2212382A1 (en) 1996-08-29
DE69632395D1 (de) 2004-06-09
CA2212382C (en) 2009-04-28
DE69632395T2 (de) 2005-05-04
EP0812209B1 (en) 2004-05-06
WO1996025942A1 (en) 1996-08-29
JPH11500443A (ja) 1999-01-12

Similar Documents

Publication Publication Date Title
DK0812209T3 (da) Cochleatleveringsvehikel til biologisk relevante molekyler
MY107276A (en) Method and formulation employing type ii endoglycosidase
ITTO960078A0 (it) Disposizione di fissaggio di guarniture in particolare minuteria per mobili.
CA2265635A1 (en) Skin care compositions containing combinations of compounds for mimicking the effect on skin of retinoic acid
DK0457849T3 (da) Klæbemiddel til elektrotransport
CA2246754A1 (en) Cochleate delivery vehicles
UA22113C2 (uk) Радіальhий підшипhик
ES2174768T1 (es) Genes de corynebacterium glutamicum que codifican proteinas del sistema fosfoenolpiruvato: azucar fosfotransferasa.
DE69008080D1 (de) Verdampfungsvorrichtung für flüssigen Brennstoff.
ITTV930005A0 (it) Struttura di dispositivo di frenatura, particolarmente per pattini conruote in linea
IT1293978B1 (it) Vasca di fermentazione, particolarmente per la vinificazione in rosso.
ITTV950058A0 (it) Struttura di dispositivo frenante, particolarmente per pattini con ruote in linea
BR9507156A (pt) Enzimas codificadoras de dna da via glicolítica para uso em levedura para produção de álcool
IT1274289B (it) Dispositivo per il disassamento di ruote, particolarmente per pattini con ruote in linea
ITBZ930004V0 (it) Disposizione di tassello,in particolare per il fissaggio di guarnitu- re per mobili.
IT8821824A0 (it) Posteggio di presentazione per autoveicoli, in particolare per automobili o autoveicoli per servizio promiscuo.
ES1004636U (es) Dispositivo de separacion transversal para estanterias lineales, gondolas y colocaciones lineales del mismo tipo.
SE9600759L (sv) Möbelsystem
ES1026720Y (es) Cartela para estanterias.
DE60127389D1 (de) Pharmazeutische träger zusammensetzung für produkte auf basis von papain
ES1012210Y (es) Perfeccionamientos en las bombas de alimentacion de gasolina.
IT1267882B1 (it) Uso alternativo della molecola di o-(b-idrossietil)-rutosidea.
ES1025209Y (es) Despositivo de sujecion para estantes en muebles.
IT1287378B1 (it) Gruppo frenante per pattini con ruote in linea.
IT209863Z2 (it) Struttura perfezionata di espositore pubblicitario, in particolare espositore da vetrina.